Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD

NCT07292012 is registered in ClinicalTrials.gov with Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives as lead sponsor.

NCT NCT07292012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07292012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD
Lead sponsor
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Phase
Phase 4
Overall status
Recruiting
Start date
May 11, 2026
Completion date
November 30, 2028
Enrollment
75 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd)